The Niu team (58) developed a non-covalent peptide PROTAC targeting GPX4, referred to as Au-PGPD (peptide GPX4 PROTAC drug), based on the elevated GPX4 expression in ALL cells. The gene discussed is GPX4; the disease is acute lymphoblastic leukemia.